Wayne State University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Johns Hopkins University

Kennedy Krieger Institute, Inc.

Sujatha Kannan

Kannan Rangaramanujam

Roberto Romero

Raghavendra S Navath

Anupa R Menjoge

Raymond Iezzi

Hui Dai

Siva Pramodh Kambhampati

Rishi Sharma

Rangaramanujam M Kannan

Bharath Rajaguru

Fan Zhang

Bharath Raja Guru

Anjali Sharma

Zhi Zhang

Kannan M Rangaramanujam

Raghavendra Navath

Anupa Menjoge

Bela Turk

Ozgul Gok

Diego F Nino

David Hackam

Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. ˜120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.

Dendrimer delivery system and methods of use thereof

Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.

Dendrimers for sustained release of compounds

Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 &#x3bc;m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 &#x3bc;m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.

Injectable dendrimer hydrogel nanoparticles

A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.

Dendrimer based nanodevices for therapeutic and imaging purposes

The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 &#x3bc;m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 &#x3bc;m and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging.

Growing community of inventors

Detroit, MI, United States of America

Sujatha Kannan